Patents by Inventor Udo Bauer
Udo Bauer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 7812026Abstract: The present invention relates to novel imidazole derivatives having a positive allosteric GABAB receptor (GBR) modulator effect, methods for the preparation of said compounds and to their use, optionally in combination with a GABAB agonist, for the inhibition of transient lower esophageal sphincter relaxations, for the treatment of gastroesophageal reflux disease, as well as for the treatment of functional gastrointestinal disorders and irritable bowel syndrome (IBS). The compounds are represented by the general formula (I) wherein R1, R2, R3 and R4 are as defined in the description. For example, R1 may be phenyl, R2 may be dimethylamino pyrrolidin-1-yl, R3 may be alkoxy and R4 may be alkyl, ai arylalkyl, aryloxyalkyl, aryloxy or heterocyclylalkyl.Type: GrantFiled: December 21, 2006Date of Patent: October 12, 2010Assignee: AstraZeneca ABInventors: Udo Bauer, Wayne Brailsford, Linda Gustafsson, Tor Svensson
-
Patent number: 7745474Abstract: The present invention relates to novel imidazole derivatives having a positive allosteric GABAB receptor (GBR) modulator effect, methods for the preparation of said compounds and to their use, optionally in combination with a GABAB agonist, for the inhibition of transient lower esophageal sphincter relaxations, for the treatment of gastroesophageal reflux disease, as well as for the treatment of functional gastrointestinal disorders and irritable bowel syndrome (IBS). The compounds are represented by the general formula (I) wherein R1, R2, R3 and Y are as defined in the description. For example, R1 may be phenyl, R2 may be dimethylamino, R3 may be alkoxy and Y may be a thioylamino- or methyl eneamino- linked substitutuent containing an aryl group.Type: GrantFiled: December 21, 2006Date of Patent: June 29, 2010Assignee: AstraZeneca ABInventors: Udo Bauer, Wayne Brailsford, Linda Gustafsson, Tor Svensson, Maria Saxin
-
Patent number: 7718686Abstract: The present invention relates to novel compounds having a positive allosteric GÀBAB receptor (GDR) modulator effect, methods for the preparation of said compounds and to their use, optionally in combination with a GABAB agonist, for the inhibition of transient lower esophageal sphincter relaxations, for the treatment of gastroesophageal reflux disease, as well as for the treatment of functional gastrointestinal disorders and irritable bowel syndrome (IBS). A compound of the general formula I.Type: GrantFiled: June 20, 2005Date of Patent: May 18, 2010Assignee: AstraZeneca ABInventors: Udo Bauer, Wayne Brailsford, Vijay Chhajlani, Bryan Egner, Ola Fjellström, Linda Gustafsson, Jan Mattsson, Karolina Nilsson, Thomas Olsson
-
Publication number: 20090149474Abstract: The present invention relates to novel imidazole derivatives having a positive allosteric GABAB receptor (GBR) modulator effect, methods for the preparation of said compounds and to their use, optionally in combination with a GABAB agonist, for the inhibition of transient lower esophageal sphincter relaxations, for the treatment of gastroesophageal reflux disease, as well as for the treatment of functional gastrointestinal disorders and irritable bowel syndrome (IBS). The compounds are represented by the general formula (I) wherein R1, R2, R3 and R4 are as defined in the description. For example, R1 may be phenyl, R2 may be dimethylamino pyrrolidin-1-yl, R3 may be alkoxy and R4 may be alkyl, ai arylalkyl, aryloxyalkyl, aryloxy or heterocyclylalkyl.Type: ApplicationFiled: December 21, 2006Publication date: June 11, 2009Inventors: Udo Bauer, Wayne Brailsford, Linda Gustafsson, Tor Svensson
-
Publication number: 20090062365Abstract: The present invention relates to novel pyrazole derivatives having a positive allosteric GABAB receptor (GBR) modulator effect, methods for the preparation of said compounds and to their use, optionally in combination with a GABAB agonist, for the inhibition of transient lower esophageal sphincter relaxations, for the treatment of gastroesophageal reflux disease, as well as for the treatment of functional gastrointestinal disorders and irritable bowel syndrome (IBS). The compounds are represented by the general formula (I) wherein R1, R2, R3 and Y are as defined in the description. For example, R1 may be hydrogen or alkyl, R2 may be hydrogen or alkyl, R3 may be alkoxy and Y may be a carbonylamino linked substituent containing an aryl group.Type: ApplicationFiled: December 21, 2006Publication date: March 5, 2009Inventor: Udo Bauer
-
Publication number: 20090005428Abstract: The present invention relates to novel compounds having a positive allosteric GABAB receptor (GBR) modulator effect, methods for the preparation of said compounds and to their use, optionally in combination with a GABAB agonist, for the inhibition of transient lower esophageal sphincter relaxations, for the treatment of gastroesophageal reflux disease, as well as for the treatment of functional gastrointestinal disorders and irritable bowel syndrome (IBS).Type: ApplicationFiled: December 21, 2006Publication date: January 1, 2009Inventors: Udo Bauer, Wayne Brailsford, Linda Gustafsson, Tor Svensson, Maria Saxin
-
Publication number: 20080312291Abstract: The present invention relates to novel thiazole and oxazole derivatives having a positive allosteric GABAB receptor (GBR) modulator effect, methods for the preparation of said compounds and to their use, optionally in combination with a GABAB agonist, for the inhibition of transient lower esophageal sphincter relaxations, for the treatment of gastroesophageal reflux disease, as well as for the treatment of functional gastrointestinal disorders and irritable bowel syndrome (IBS). The compounds are represented by the general formula (I) wherein X1 and X2 are selected from 0 and N or S and N and R1, R2 and Y are as defined in the description. For example, R1 may be alkyl, alkoxy, thioalkoxy or aryl, R2 may be alkoxy and Y may be a carbonylamino-linked substituent containing an aryl or heteroaryl group.Type: ApplicationFiled: December 21, 2006Publication date: December 18, 2008Inventors: Udo Bauer, Linda Gustafsson, Maria Saxin, Tor Svensson
-
Publication number: 20080312305Abstract: The present invention relates to novel imidazole derivatives having a positive allosteric GABAB receptor (GBR) modulator effect, methods for the preparation of said compounds and to their use, optionally in combination with a GABAB agonist, for the inhibition of transient lower esophageal sphincter relaxations, for the treatment of gastroesophageal reflux disease, as well as for the treatment of functional gastrointestinal disorders and irritable bowel syndrome (IBS). The compounds are represented by the general formula (I) wherein R1, R2, R3 and R4 are as defined in the description. For example, R1 may be alkyl or arylalkyl, R2 may be alkyl, R3 may be alkoxy and R4 may be a substituent containing an aryl group.Type: ApplicationFiled: December 21, 2006Publication date: December 18, 2008Inventors: Udo Bauer, Linda Gustafsson, Maria Saxin
-
Publication number: 20080269216Abstract: The present invention relates to novel compounds having a positive allosteric GÀBAB receptor (GDR) modulator effect, methods for the preparation of said compounds and to their use, optionally in combination with a GABAB agonist, for the inhibition of transient lower esophageal sphincter relaxations, for the treatment of gastroesophageal reflux disease, as well as for the treatment of functional gastrointestinal disorders and irritable bowel syndrome (IBS).Type: ApplicationFiled: June 20, 2005Publication date: October 30, 2008Inventors: Udo Bauer, Wayne Brailsford, Vijay Chhajlani, Bryan Egner, Ola Fjellstrom, Linda Gustafsson, Jan Mattsson, Karolina Nilsson, Thomas Olsson
-
Publication number: 20080262064Abstract: The present invention relates to novel imidazole compounds having a positive allosteric GABAB receptor (CUR) modulator effect, methods for the preparation of said compounds and to their use, optionally in combination with a GABAB agonist, for the inhibition of transient lower esophageal sphincter relaxations, for the treatment of gastroesophageal reflux disease, as well as for the treatment of functional gastrointestinal disorders and irritable bowel syndrome (IBS).Type: ApplicationFiled: April 17, 2008Publication date: October 23, 2008Applicant: ASTRAZENECA ABInventors: Udo Bauer, Wayne Brailsford, Leifeng Cheng, Maria Jonforsen, Florian Raubacher, Peter Schell, Tor Svensson
-
Patent number: 6462063Abstract: The present invention relates to a novel class of N,N′-di substituted hydantoin hydroxamates capable of inhibiting C-proteinase, and to their use to regulate, modulate and/or inhibit abnormal collagen formation as a therapeutic approach towards the treatment of fibrotic disorders.Type: GrantFiled: February 4, 2000Date of Patent: October 8, 2002Assignee: Fibrogen, Inc.Inventors: Wen-Bin Ho, Udo Bauer
-
Patent number: 6425420Abstract: A process and device for decanting dental filling substances (2) into special individual containers (3) for use in dental treatment. Storage container (1) is connected leakproof and pressure sealed to conically shaped jet (4) of individual container (3). By applying pressure, dental filling substance (2) is squeezed from storage container (1) through jet (4) into the container body, thereby pushing ahead of it axially movable piston (7) until same reaches a final position determined by circuit-controlled limit stop (10). Thus, a precise dosage can be guaranteed during a long service life, even while filling several individual containers (3) simultaneously. Sensor (11), placed within the range of limit stop (10), records the final position of stop rod (6) conveying the movement of piston (7).Type: GrantFiled: April 6, 2001Date of Patent: July 30, 2002Assignee: Degussa AGInventors: Adam Both, Ulrich Kläres, Ralf Luckau, Michael Roth, Udo Bauer
-
Publication number: 20020007863Abstract: A process and device for decanting dental filling substances (2) into special individual containers (3) for use in dental treatment. Storage container (1) is connected leakproof and pressure sealed to conically shaped jet (4) of individual container (3). By applying pressure, dental filling substance (2) is squeezed from storage container (1) through jet (4) into the container body, thereby pushing ahead of it axially movable piston (7) until same reaches a final position determined by circuit-controlled limit stop (10). Thus, a precise dosage can be guaranteed during a long service life, even while filling several individual containers (3) simultaneously. Sensor (11), placed within the range of limit stop (10), records the final position of stop rod (6) conveying the movement of piston (7).Type: ApplicationFiled: April 6, 2001Publication date: January 24, 2002Inventors: Adam Both, Ulrich Klares, Ralf Luckau, Michael Roth, Udo Bauer
-
Patent number: 4136141Abstract: A commodity to be packaged in a carton, box or another type of container is foamed in place while being held by distancing elements which extend into the interior of the container. The distancing elements are retracted upon completion of the foaming step, either through the open top or through openings in the top, bottom and/or side walls of the container.Type: GrantFiled: April 6, 1977Date of Patent: January 23, 1979Assignee: Klein, Schanzlin & Becker AktiengesellschaftInventors: Udo Bauer, Jurgen Nothdurft, Willi Langer